Organon & Co | OGN - Ebitda

Stock Price
13.40
Daily Change
0.04 0.30%
Monthly
43.62%
Yearly
48.48%
Q2 Forecast
13.13

Organon & Co reported $415M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Celltrion KRW 17.79B 356.77B Dec/2025
Cspc Pharmaceutical CNY 2.19B 21.88M Dec/2024
Deva Holding AS TRY 882.9M 201.7M Sep/2023
Dianthus Therapeutics USD -40.19M 5.36M Sep/2025
Divis Laboratories Ltd INR 8.9B 20M Dec/2025
Gilead Sciences USD 3.02B 1.01B Dec/2025
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
Kangmei Pharma CNY 17.3M 20.56M Jun/2025
Knight Therapeutics CAD 24.45M 3.46M Dec/2025
Laboratorios Farma EUR 34.94M 102.95M Jun/2025
Malin Corporation EUR -1.1M 200K Dec/2024
Medical Developments International AUD 1.78M 3.78M Dec/2024
Merck USD 6.3B 2.09B Dec/2025
Neuren Pharmaceuticals AUD 11.14M 165.56M Dec/2025
Novartis USD 5.84B 235M Sep/2025
Organigram Holdings CAD 5.26M 884K Dec/2025
Organon & Co USD 415M 32M Mar/2026
Pharma Mar EUR 2.71M 42.25M Mar/2026
Qiagen NV USD 249.69M 56.53M Dec/2025
Sartorius EUR 267.3M 10.1M Mar/2026
Sino Biopharmaceutical CNY 2.59B 1.57B Dec/2024
Tilray USD 8.36M 1.82M Sep/2025
Zealand Pharma A/S -727.47M 285.54M Dec/2025